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NK cells are components of the innate immunity system and play an important role as a ﬁrst-line defense mechanism against viral
infections and in tumor immune surveillance. Their development and their functional activities are controlled by several factors
among which cytokines sharing the usage of the common cytokine-receptor gamma chain play a pivotal role. In particular, IL-2,
IL-7,IL-15,andIL-21arethemembersofthisfamilypredominantlyinvolvedinNKcell biology.In thispaper,wewill address their
role in NK cell ontogeny, regulation of functional activities, development of specialized cell subsets, and acquisition of memory-
like functions. Finally, the potential application of these cytokines as recombinant molecules to NK cell-based immunotherapy
approaches will be discussed.
1.Background:The Common-GammaChain
CytokineFamily
Cytokines are soluble mediators of intercellular signals and
play an essential role in the activation and regulation of both
adaptive and innate immunity. In particular, the family of
cytokines, sharing the common cytokine-receptor gamma-
chain (γc or CD132) in their receptor complexes, consists
of several members with a similar four alpha-helix bundle
structure. This family comprises interleukin (IL)-2, IL-4,
IL-7, IL-9, IL-15, and IL-21, which display functional
redundancy in the regulation ofthe immune response and in
thehomeostasisofthelymphoidsystembuthavealsospeciﬁc
functions [1]. Each of these cytokines binds to a speciﬁc
high aﬃnity receptor complex formed by a cytokine-speciﬁc
α chain and the γc [2, 3]( Figure 1). Diﬀerent from other
members of this family, IL-2 and IL-15 can bind with high
aﬃnity to heterotrimeric receptor complexes, which con-
sist of IL-2Rα (CD25) or IL15-Rα, respectively, and of
IL-2Rβ (CD122) and γc chains [4, 5]. The γc is an essential
component of the receptors of all these cytokines, as it
associates to the Janus tyrosine-kinase (JAK)-3, which is
required for signal transduction [6]. JAK-3 phosphorylates
diﬀerentdownstreamsignaltransducerandactivatoroftran-
scription (STAT) molecules, in relationship to the type of
the receptor complex involved (Figure 1). Thus, IL-4 pre-
dominantlysignals throughSTAT-6,whereas IL-2,IL-7,IL-9,
and IL-15 mainly activate STAT-5, and IL-21 acts through
STAT-3 and STAT1 [1, 7]. The activation of diﬀerent STAT
proteinsby JAK-3isrelated to itsabilityto phosphorylate the
intracytoplasmic tail of diﬀerent receptor chains. Tyrosine-
phosphorylation of aminoacidic motifs in cytokine-speciﬁc
receptor molecules generates docking sites for speciﬁc
unphosphorylated STAT monomers, which are recruited to
the receptor complex through their SH-2 domains [8]. Upon
tyrosine phosphorylation by JAK-3, phosphorylated STAT
molecules dimerize and migrate into the nucleus, where
they bind to STAT-sensitive regulatory elements and control2 Journal of Biomedicine and Biotechnology
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Figure 1: The family of cytokines sharing the common cytokine-receptor γc in their receptor complexes. Each cytokine binds to a speciﬁc
α chain, which forms a receptor complex with the γc. In case of IL-2 and IL-15, trimeric high aﬃnity complexes, which include common
IL-2Rβ and γc chains, can be formed. Each receptor complex mediates signal transduction through JAK1 and/or JAK3 and diﬀerent STAT
molecules. Tyr-phosphorylated STAT dimers regulate transcription of speciﬁc cytokine-sensitive genes.
transcription of speciﬁc genes. Both the γc and JAK3 are
essential for the function of all cytokine receptors of this
family and are required forthe developmentof the lymphoid
cell system. Indeed, genetic defects of γc or JAK-3 results in
a severe combined immune deﬁciency (SCID) characterized
by the lack of T, B, and NK cells in both mice and humans
[9]. In addition to JAK-3, some receptor complexes also
activateJAK-1,which predominantlyphosphorylatesSTAT-1
molecules.
IL-2 is the ﬁrstly identiﬁed member of this cytokine
family, and its gene was originally cloned on the basis of
the T-cell growth factor (TCGF) activity of this cytokine
[10, 11]. Besides its TCGF activity, IL-2 upregulates NK cell
proliferation and function, induces lymphokine-activated
killer (LAK) activity, and also mediates activated B cell
proliferationandIgproduction[12].IL-4playsanimportant
role in T helper (Th)2 cell development and function, in
the regulation of B cell responses, and particularly in IgE
production. Therefore, it is involved in allergic diseases and
defense against parasitic infections [13]. Few eﬀects of IL-
4 have been reported on NK cells. Recent data indicate
that IL-4 downregulates the expression of the activating
receptorNKG2DinmouseNKcells,thusinhibitingNKG2D-
dependent killing in vitro and in vivo [14]. In addition, IL-
4 can also inhibit Ly49 receptors expression [15], suggesting
a functional role in the innate immunity response. Finally,
human NK cells cultured for short term with IL-4 did not
release interferon (IFN)-γandshowed nocytolyticactivityin
response to stimulation through NKp46-activating receptor.
In contrast, IL-12-cultured NK cells released IFN-γ and
displayed strong cytolytic activity against tumor cells or
immature dendritic cells (DC). These data suggest that IL-4
may negatively inﬂuence the NK/DC cross-talk, impair Th1
priming, and favor tolerogenic or Th2 responses in humans
[16]. Diﬀerent from the two previous cytokines, which
mainly regulate the immune response, IL-7 is fundamental
for the homeostasis of the immune system, as it regulates
T, B, and NK lymphoid cell development [17]. Indeed, IL-7
is produced by thymic and bone marrow epithelial and
stromal cells and by reticular cells in peripheral lymphoid
tissues. IL-7 supports diﬀerentiation of hematopoietic stem
cells into lymphoid progenitor cells and proliferation and
survival of lymphoid precursor cells in the bone marrow and
in the thymus. In addition, it stimulates survival of naive and
memory T cells in the periphery. The crucial role of IL-7
in lymphoid cell development is clearly evidenced by the T
and B-cell deﬁcient SCID phenotype of patients and mice
with genetic defects of the IL-7Rα (CD127) chain [16, 18].
AlthoughIL-7Rα-deﬁcientpatientsandmicedonothaveNK
cell deﬁciency, several data indicate that IL-7 is involved in
the developmentof speciﬁc subsets of NK cells [19–24]. IL-9
is a proinﬂammatory cytokine released by activated CD4+ T
cells and mediates activation of eosinophils, mast-cells, and
bronchial epithelial cells, thus playing a relevant role in
asthma [25]. However, IL-9 appears not involved in NK cell
regulation. IL-15, instead, plays a pivotal role in NK cell
biology. This cytokine shares several functional activities of
IL-2duetothepromiscuoususagenotonlyoftheγc,butalso
of the IL-2Rβ chain [4, 12, 26]. However, diﬀerently from
IL-2, IL-15 is expressed in several tissues and it is produced
by diﬀerent nonlymphoid cell types such as monocytes, DC
and stromal cells of the bone marrow and thymus [5]. IL-15
producedinbone marrow, thymus, and secondary lymphoid
organs is a crucial element to drive the development andJournal of Biomedicine and Biotechnology 3
survival of NK cells [27–29] and of certain subsets of T cells
[27, 28]. Finally, IL-21, the most recently identiﬁed member
of this cytokine family [30] was originally discovered as
the ligand of an IL-2Rβ-related orphan receptor [31], now
termed IL-21R. IL-21 can costimulate the proliferation of T,
B, and NK cells and promotes the terminal diﬀerentiation of
IL-15 activated NK cells and of activated B cells into plasma
cells [32]. In addition, IL-21 mediates apoptosis of partially
activatednormalBcells[33]andofcertainhumanneoplastic
B cells [34–37].
This paper will focus on the role of IL-2, IL-7, IL-15, and
IL-21 in NK cell development and function and will discuss
the possible relevance of NK activation by these cytokines in
cancer immunotherapy.
2.DistinctRoleof IL-2and IL-15in
NK CellBiology
IL-2andIL-15shareseveralfunctionalpropertiesinrelation-
ship totheuseoftwopromiscuousreceptorcomponents(IL-
2Rβ and γc) and common signaling pathways. Indeed, both
cytokines stimulate the proliferation, survival, and func-
tional activities of NK cells and activated T and B cells.
Nonetheless, the two cytokines have also speciﬁc functions,
which are related to the diﬀerent cellular distribution and
functional properties of the IL-2Rα and IL-15Rα chains and
the to the distinct cellular origin and regulation of IL-2 and
IL-15 production [12].
IL-2 may act through two types of receptor complexes:
thehighaﬃnity trimeric receptorformedbyIL-2Rα,IL -2Rβ,
and γc and an intermediate aﬃnity dimeric receptor formed
by the IL-2Rβ and γc.W h i l et h eh i g ha ﬃnity trimeric recep-
tor is expressed on activated T and NK cells, the intermediate
receptor is constitutively expressed on CD3−CD56+CD16+
NK cells [38] and on minor subsets of T cells, which can
directly respond to high concentrations of IL-2. The consti-
tutive expression of functional IL-2R accounts for the induc-
tion of LAK cells, displaying broad non-MHC restricted
cytolytic activity against diﬀerent types of tumor cells by
short-term culture of PBMC in IL-2-containing medium
[39]. Indeed, LAK cells are predominantly represented by
IL-2-activated NK cells and by a subset of T cells [40].
However, a subset of human CD3−CD56brightCD16− NK
cells constitutively express high aﬃnity IL-2 receptors and
may respond to low IL-2 concentrations [41, 42].
The IL-2 and IL-15 receptor α chains display remarkable
diﬀerences. IL-2Rα alone has a low aﬃnity for IL-2 and is
devoid of signaling properties although it is required for the
generationofhigh-aﬃnity trimeric IL-2Rcomplexes.IL-2Rα
expression is induced in T cells upon activation; however,
it is constitutively expressed at high levels on immune sup-
pressive CD4+CD25+FoxP3+ regulatory T (Treg) cells [43].
Indeed,IL-2playsaspeciﬁcroleinimmuneregulationandin
peripheraltolerance[44],as itis involvedin themaintenance
and ﬁtness of CD4+CD25+FoxP3+ Treg cells [45, 46]. In
addition, IL-2 participates in activation-induced cell death
of T cells, which limits T cell responses [47]. The primary
role of IL-2 in immune regulation is evidenced by the study
of mice defective of IL-2 [48]o ro fI L - 2 R α [49] genes,
which develop a lymphoproliferative disorder associated
with autoimmunity and impaired Treg function. The genetic
defect of the IL-2Rβ chain results in autoimmunity in mice
and also in a unique NK-deﬁcient immunophenotype in
mice [50] and humans [51]. In addition, an NK cell defect is
part of the SCID phenotype in humans [52]a n dm i c e[ 53]
bearing genetic defects of the γc. Altogether, these studies
indicated that IL-2 or IL-2Rα are not necessary for NK cell
development, although the IL-2Rβ and the γc are strictly
required, suggesting a role for IL-15. Indeed, IL-15 and its
speciﬁc receptor IL-15Rα are essential for the generation and
maintenance of NK cells, as IL-15 mediates the development
of NK cells from committed NK cell precursors, promotes
the diﬀerentiation of immature NK cells, and supports the
survival of mature NK cells in the peripheral lymphoid
organs [54–56].
Diﬀerent from IL-2Rα, IL-15Rα alone has a high aﬃnity
for IL-15 and is constitutively expressed in several lymphoid
and nonlymphoid cell types [57, 58]. The study of IL-
15- [28] or IL-15Rα-KO [27] mice, which have similar
NK-deﬁcient phenotypes, conﬁrmed that the IL-15/IL-15Rα
system has an unique essential role in the development
and survival of NK cells and of certain subsets of T cells
such as NKT cells and intestinal intraepithelial CD8αα+ T
cells. In addition, IL-15Rα deﬁcient mice have a reduced
CD8+CD44high memory T cell pool, indicating a critical role
of this receptor in the maintenance of a CD8 memory.
Similar to IL-2, IL-15 can mediate conversion of poorly
cytolytic resting NK cells into highly cytolytic eﬀector NK
cells, which acquire enhanced antitumor activity [59]. Rest-
ing murine NK cells contain abundant granzyme A, but little
granzyme B or perforin while the mRNAs for all three genes
are highly expressed. IL-2 or IL-15 mediate a dramatic in-
crease in granzyme B and perforin proteins without altering
their mRNA abundance. These data suggest that these
cytokines can mediate the removal of a block of perforin and
granzyme B mRNAtranslation that preventsresting NKcells
to be fully cytotoxic [60].
Several evidences indicate that IL-15 supports NK cell
survival [12, 29] and is more potent than IL-2 in this respect.
The antiapoptotic eﬀects of IL-15 on murine NK cells are
mediated through the inhibition of Bim expression by dif-
ferent mechanisms involving Erk-1/2 phosphorylation orthe
phosphatidylinositol-3-OH kinase (PI(3)K)-dependent in-
activation ofthe transcription factor Foxo3a.Inaddition, IL-
15 also promotes NK cells survival by the upregulation of
Mcl-1,amoleculethatwaspreviouslyreportedtoberequired
for the development and survival of T and B lymphocytes
[61].
Recent observations indicate that IL-2 or IL-15-activated
NK cells display a diﬀerent sensitivity to corticosteroids.
The corticosteroid methylprednisolone inhibited the surface
expression of the activating receptors NKp30 and NKp44
and cytolytic activity in IL-2- or IL-15-cultured human NK
cells. However, proliferation and survival were inhibited
in IL-2- but not in IL-15-cultured NK cells. Moreover,
methylprednisolone inhibited activation of STAT-1, STAT-
3, and STAT-5 in IL-2-cultured NK cells but only partially in4 Journal of Biomedicine and Biotechnology
IL-15-culturedNKcells.Thisstudyindicatesadistinctability
of IL-15-cultured NKcells to survive to steroid treatment, an
observation thatis important in immune disorders requiring
this drug [62].
Other important diﬀerences between IL-2 and IL-15
concern their regulation of expression and secretion. IL-2
gene is transcriptionally activated in Th cells in response
to antigen presentation, and then activated Th cell release
soluble IL-2, which can activate lymphoid cells expressing
highorintermediateaﬃnityreceptorcomplexes.Bycontrast,
IL-15 gene is constitutively expressed in several normal cell
types, such as monocytes, DC, stromal cells, epithelial cells
and also in some human neoplastic cells [5, 63]. Two IL-
15 mRNA isoforms generated by alternative splicing have
beenidentiﬁed in humancells: one encodesfora short signal
peptide (SSP)-IL-15 and the other for a long-signal peptide
(LSP)-IL-15 isoform [64, 65]. The two isoforms show a
diﬀerent intracellular traﬃcking, as the SSP-IL-15 predom-
inantly localize to the cytoplasm and nucleus, whereas the
LSP-IL-15 enters in the endoplasmic reticulum [66]. As a
consequence the SSP-IL-15 isoform is not secreted and may
have regulatory intracellular functions, whereas the LSP-
IL-15, which is usually more expressed, can be potentially
exported outside the cell. Nonetheless, it appeared that
only very limited amounts of IL-15 are secreted by IL-15
mRNA-expressing cells, possibly in relationship to its low
translational rate, to ineﬃcient secretion, and/or to putative
retention motifs in the COOH terminus [65–68]. Thus,
multiple mechanisms may regulate IL-15 production and
secretion.
3. Role of Cytokines in NK Cell Interactions in
SecondaryLymphoidOrgans
The expression of IL-15 in stromal cells of primary and
secondary lymphoid organs and the deﬁciency of NK cells
in mice with genetic defects of the IL-15/IL-15R system
indicate a primary role of IL-15 in NK cell development
and homeostasis [69–71]. Nonetheless, several data support
an important role of a DC/NK cell cross-talk, primarily
mediated by cytokines, in the immune response and defense
against pathogensin mice [72] and humans [73].Inbacterial
infections the interaction between human NK and DC cells
may lead to NK cell proliferation, activation, and cytolytic
activity [73].
Stimulation in vitro with IL-15, IL-2, IL-1 or IL-18 or
engagement of activating receptors (i.e., CD16 or NKG2D)
in combination with IL-12 induces production of IFN-γ and
of other proinﬂammatory cytokines and chemokines, such
as tumor-necrosis factor (TNF)-α and macrophage inﬂam-
matory protein (MIP)-1α by human NK cells [74, 75]. It
is of note that cytokines that co-activate NK cells may be
produced by monocytes/macrophages or DC and, in this
context, it has been shown that DCs colocalize with NK cells
in the T cell areas of lymph nodes. Membrane-bound IL-15
is highly exspressed on human DCs activated through CD40
engagement, and is essential for NK cell proliferation and
survival. Thus, secondary lymphoid organs are important
sites for DC/NKcell interactions [76].
Human CD3−CD56+ NKp46+ NK cells are a heteroge-
neous cell population. The CD56dimCD16+ cells, predomi-
nant in peripheral blood, were originally described as strong
cytotoxic eﬀectors with low ability to produce cytokines,
by contrast, the CD56brightCD16− NK cell subset, the most
represented in secondary lymphoid organs, has been re-
ported to be the most potent producer of IFN-γ but
provided of low cytolytic activity [77]. A recent study of
De Maria et al. [78] reevaluated the functional capabilities
of the two major human NK subsets and showed that
NKp46 and NKp30-mediated stimulation induces an early
(at 2–4h from stimulation) and abundant production of
IFN-γ by CD56dimCD16+ NK cells in relationship to the
constitutive expression of IFN-γ mRNA. However, IFN-γ
production was transient and no more cytokine production
by this cell subset is observed after 16 h from stimulation,
when CD56brightCD16+/− cells begin to release IFN-γ. IFN-
γ production by the two NK subsets is also observed upon
exposure to cytokine combinations such as IL-12+IL-2 or
IL-12+IL-15. In this case, CD56dimCD16+ NK cells show
early but persistent response to stimulation. Therefore,
CD56brightCD16+ NK cells may play an important role in the
early phases of innate responses and in the cross-talk with
DC.
Diﬀerent from CD56dim,C D 5 6 brightNK cells constitu-
tively express the high-aﬃnity heterotrimeric IL-2 receptor
complex [41, 42] and can, therefore, respond to picomolar
concentrations of IL-2 produced by Th cells. Costimulation
of CD56bright human NK cells with IL-2 and IL-12 produced
by DC triggers the production of IFN-γ [75]. IFN-γ can
further activate DCs and inﬂuence the polarization of the
Th cell response to Th1. In addition, activated NK cells
also produce TNF-α and granulocyte-macrophage colony-
stimulating factor(GM-CSF),which supportDCdiﬀerentia-
tionand maturation.Therefore, CD56bright NKcellsmay link
the innate- and antigen-speciﬁc immune response, through
an NK/DC cross-talk, and shape the adaptive immune re-
sponse [79, 80].
4.Involvement of Trans-Presentationin
IL-15 Activity
The lack of detectable IL-15 secretion, in contrast with its
traﬃcking from the secretory compartment to the early
endosomes in some IL-15-expressing human melanoma
cells, suggested a possible juxtacrine activity of IL-15. In this
early model, IL-15-mediated eﬀects required cell to cell
proximity (Figure 2) and could be blocked by an anti-IL-15
monoclonal antibody (mAb) [81]. Further studies showed
that IL-15 is expressed as membrane-bound molecule in
IFN-γ-stimulated human monocytes, which are capable
to stimulate T cell proliferation [82]. In addition, IL-15-
mediated proliferation of mouse T cells, triggered by Poly
I:C, did not require IL-15Rα on the T cells but instead
was dependent on the IL-15Rα present on surrounding
cells [83]. These ﬁndings could be later explained by theJournal of Biomedicine and Biotechnology 5
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Figure 2: Diﬀerent mechanisms of IL-15 action. (a): Low levels of secreted IL-15 can bind to high aﬃnity trimeric receptors through
a juxtacrinemechanism.(b):IL-15 binds to the high-aﬃnityIL-15Rα chain withinthe endoplasmicreticulum andis then shuttledto the cell
membrane as a complex. (c): IL-15Rα can trans-present IL-15 to an apposing IL-2Rβ/γc
+ NK cell through cell contact. (d): The possibility
of cis-presentation by IL-15Rα/IL-15 membrane complex to an IL-2Rβ/γc heterodimer on the same NK cell is shown. (e): A soluble sushi
domain-IL-15Rα bound to IL-15 can perform trans-presentation in a soluble form. (f): Soluble IL-15Rα extracellular domain generated by
metalloprotease cleavage can bind soluble IL-15 and block its function.
trans-presentation of IL-15 through IL-15Rα.F o rt r a n s -
presentation, exogenous IL-15 binds to cell surface IL-
15Rα chain, the complex is internalized, recycled at the cell
membrane and trans-presented to apposing T cells express-
ing IL-2Rβ/γc heterodimers (Figure 2(c)) [84]. Alternatively,
endogenously produced LSP-IL-15 binds into the endoplas-
mic reticulumwith IL-15Rα,is exported onto thecell surface
of human spleen ﬁbroblasts as a complex with the IL-15Rα
chain (Figures 2(b) and 2(c)). The trans-presentation of IL-
15 to bystander haematopoietic progenitors commits these
cells to the NK diﬀerentiation pathway [85]. Similar results
have been reported in murine bone marrow DC, where IL-
15Rα/IL-15 cell membrane complexes activate NK cells via
trans-presentation [86]. The study of in vivo models further
supported the role of trans-presentation in peripheral NK
cell activation and survival. Indeed, adoptive transfer of
normal NK cells into mice lacking the IL-15Rα results in the
rapid disappearance of these cells. Conversely, IL-15Rα-
deﬁcient NK cells survive upon transfer in normal but not
in IL-15Rα-deﬁcient mice. Collectively these data show that
IL-15Rα expression on surrounding cells is crucial for the
survival of peripheral NK cells, while IL-15Rα expression on
NK cells is not involved [87] .T h eﬁ n d i n gt h a tb o n em a r r o w
progenitors from IL-15Rα−/− mice cultured with IL-7, stem
cell factor (SCF) and FMS-like tyrosine kinase 3 ligand
(FLT3L), followed by IL-15, diﬀerentiate into CD94/NKG2+
NK cells, which lacked Ly49 expression, suggest that IL-
15Rα on NK cell precursors is not required for NK cell
development but is required for their Ly-49 expression [88].
IL-15 and IL-15Rα have a broad tissue distribution,
although their expression is not always coincident, raising
the question about the cell type(s) involved in trans-pres-
entation. IL-15 trans-presented by DC has been shown to
activate NK cells both in vitro and in vivo [89]. In addition,
a study suggested that both hematopoietic cells, such as
DC and macrophages and nonhematopoietic cells, including
stromal cells and epithelial cells are involved in trans-
presentation of IL-15 to human NK cells [90]. Moreover,
mice lacking IL-15Rα on macrophages, DCs, or on both,
exhibit equivalent defects in NK cell homeostasis and acti-
vation, whereas only the expression on macrophages was
important for the development of memory CD8+ Tc e l l
responses [89].
Besides the relevance of cell-bound IL-15Rα in IL-15
trans-presentation, it has been hypothesized that IL-15Rα
may also act as a cis-presenting molecule [83, 91]. In this
model, the membrane IL-15Rα/IL-15 complex presents IL-
15 to neighbour IL-2Rβ/γc complexes on the same cell
(Figure 2(d)). In this context, previous data showed that
human CD3+ or CD3− neoplastic lymphoid cells from
lymphoproliferative disorder of large granular lymphocytes
(LDGL) express surface bound IL-15 [92]. As these cells
express IL-15Rα and proliferate to exogenous IL-15 stimu-
lation, it is possible that they may bind IL-15 in vivo and
store iton thecell membrane,thusallowing sustained stimu-
latory eﬀects of endogenous IL-15 through cis-presentation.
Nonetheless, the possible source of the in vivo bound IL-15
remains to be determined. The fact that IL-15 may not only6 Journal of Biomedicine and Biotechnology
support neoplastic NK cell proliferation but may also play a
role in the pathogenesis of LDGL was also suggested by the
observation of spontaneous LDGL-like leukemias occurring
in mice with transgenic overexpression of IL-15 [93].
In addition to trans- or cis-presentation of IL-15 by IL-
15Rα, other forms of membrane-bound IL-15, independent
from IL-15Rα, have been described. One of these IL-15
forms has been identiﬁed on human monocytes and may
behave not only as a ligand but also as a signaling molecule.
Thus, membrane-bound IL-15 may produce a reverse sig-
naling that results in cellular adhesion and production of
inﬂammatory cytokines [94]. Also, human haematopoietic
progenitors derived from peripheral blood, but not from
other sources, express an IL-15Rα-independent membrane-
bound IL-15, which mediates reciprocal intercellular signals.
This reciprocal trans-presentation induces the in vitro gen-
eration of a novel subset of mature noncytolytic NK cells
(NKireg) that display regulatory functions and express the
immunosuppressive molecule HLA-G. Remarkably, a small
subset of NKp46+HLA-G+IL-10+ is detected within freshly
isolated decidual NK cells, suggesting that these cells could
represent an in vivo counterpart of the in vitro-generated
NKireg cells [95]. In addition, these NKireg precursors
maintain along their diﬀerentiation process in vitro the ex-
pression of a membrane-IL-15 able to deliver a bidirectional
signal. Indeed, the soluble IL-15Rα chain, upon binding
with membrane-IL-15, triggers a reverse signal leading to
the appearance of an adherent subset with DC morphology.
These cells may represent a terminally diﬀerentiated popula-
tion, since they do not proliferate, display both speciﬁc NK
(NKp46) and myeloid dendritic (CD1a and BDCA1) mark-
ers as well as cytokine production and functions, illustrating
another possible chapter of the NK/DC functional interplay
[96]. Nonetheless, the in vivo signiﬁcance of these cells has
not yet been explored.
Recent evidences also indicate that soluble forms of IL-
15 receptors can be generated by either alternative splicing
or by in vivo cleavage of surface IL-15Rα through meta-
lloproteinase-driven mechanisms [97, 98]. Such natural
soluble forms of IL-15Rα corresponding to the extracellular
domain behave either as a high-aﬃnity IL-15 antagonists
(Figure 2(f)) or as superagonist, depending on the isoform
involved. Indeed, soluble IL-15RαΔ3i s o f o r mb o u n dt o
recombinant IL-15 generates a soluble complex, “hyper-IL-
15”, displaying a 100-fold higher biological activity on IL-
2Rβ/γc
+ target cells than that exerted by the soluble cytokine
[85]. Moreover, a recombinant, soluble sushi domain of IL-
15Rα, capable to bind IL-15 with high aﬃnity, is a potent
IL-15 agonist and enhances the binding and the biological
eﬀects of IL-15 mediated through the IL-2β/γ heterodimer
(Figure 2(e)). Nonetheless, the possible in vivo sources of
similar “hyper-IL-15” forms and their potential role in
the innate and adaptive immune response remains to be
determined. In addition, fusion proteins consisting of IL-15
and IL-15Rα-sushi domain linked by a ﬂexible aminoacid
sequence (RLI) are even more potent stimulators of NK and
T cells [99]. The use of RLI or of soluble IL-15 on a T
cell line expressing both IL-15Rα/IL-2Rβ/γc trimeric and IL-
2Rβ/γc dimeric complexes allowed to study the dynamics of
cis-presentation (by IL-15) or trans-presentation (by RLI).
IL-15 cis-presentation induced fast and transient activation,
while trans-presentation mediated slower and more persis-
tent responses [100].
5. Role of Cytokines in NK
“Memory-Like”Responses
In speciﬁc immunity, the expansion of antigen-speciﬁc
memorycellsandpersistentantibodyproductioninresponse
to pathogen’santigen challenge provide enhanced protection
against the same pathogen upon a subsequent exposure. By
contrast, NK cells are generally thought to be “naturally
active” cells, which constitutively display eﬀector functions
against infected or transformed cells [101] and are inca-
pable of adapting their responsiveness and of maintaining
a memory of a ﬁrst pathogen encounter in subsequent
challenges. However, it is well known that freshly isolated
NK cells show low eﬀector functions in terms of cytolytic
activity and cytokine production when incubated in vitro
with tumor target cells. Several evidences indicate that NK
cells can modify their behavior in response to environmental
stimuli and can even show memory-like responses in mouse
models [102, 103]. For example, recombinase activation
gene (RAG)−/− mice (lacking both T and B cells) but
not γc-deﬁcient mice (lacking also NK cells) can develop
delayed-type hypersensitivity (DTH) reactions to hapten.
This response was speciﬁcally mediated by a subset of liver
NK cells expressing Ly49C (an inhibitory receptor for self
MHC molecules). In addition, NK cells from sensitized mice
developa speciﬁc memory-like function, since theiradoptive
transfer intonaivemicecanmediateDTHtothesamehapten
[104].
Besides this type of memory, which appears to be linked
to expression of a speciﬁc type of receptor, NK cells may
change their way of responding to stimuli following their
exposure to speciﬁc cytokines [105]. Thus, NK cells from
RAG−/− mice,activated forshort-term withacytokinecock-
tail consisting of IL-12, IL-18, and IL-15, produce high levels
of IFN-γ in vitro. Uponsubsequent transfer into na¨ ıve hosts,
these cells can be detected up to three weeks later when
they are returned similar to resting NK cells, as they do not
display constitutive production of IFN-γ nor enhanced lytic
properties. However, they produce signiﬁcantly more IFN-
γ than na¨ ıve cells when restimulated. These data suggest
that NK cells retain memory of prior cytokine activation. In
addition, this memory-like function appeared asan inherita-
ble characteristic, as cytokine-activated NK cells proliferated
once injected in mice [105].
As already mentioned, DC can interact with NK cells
and activate them via trans-presented IL-15 in vitro [86].
Subsequent ﬁndings in a mouse model indicate that similar
to T cells, NK cells need to be primed by contact with DC
to achieve a full ability to respond to pathogen in vivo and
this priming is mediated by IL-15 [106]. Upon engagement
ofToll-likereceptorbypathogenligandsintheperiphery,NK
cells migrate into regional lymph nodes where their interact
withDCs.NKcellprimingrequiredIFN-mediatedactivationJournal of Biomedicine and Biotechnology 7
of CD11c+ DCs, which subsequently trans-present IL-15 to
NK cells. Thus priming of NK cells results in arming, as IL-
15 can confer full cytolytic properties to NK cells [60]. NK
cells become then eﬀector cells and migrate the periphery,
where they can eﬃciently respond to pathogens. Priming
and arming is a short-term response ﬁnalized to eﬀector
functions needed to eliminate pathogens. However, it has
been proposed that upon priming and arming NK cells can
further develop into memory-like NK cells, which do not
produce cytokines or display lytic properties but maintain
the capacity to respond to a subsequent pathogen challenge
in a more vigorous way than na¨ ıve NK cells [102].
Thus, several evidences suggest that NK cells are capable
to mediate memory-like responses in diﬀerent murine mod-
els, although the relevance of such responses in humans is
still to be deﬁned.
6.RoleofIL-7 inNK CellSubset Development
In addition to IL-15, which is strictly required for the gen-
eration of all NK cells [21, 28], other cytokines have been
involved in the development of speciﬁc NK cell subsets in
diﬀerent organs. In fact, it is clear that NK cells derive from
CD34+ hematopoietic progenitor cells originating in the
bone marrow. However, early NK precursors can migrate to
diﬀerentorgans, where theydiﬀerentiatetowards matureNK
cells. Thus, the development of NK cells takes place not only
i nt h eb o n em a r r o w ,b u ta l s oi nt h et h y m u s[ 107, 108], in
secondarylymphoidorgans[109]andinmucosae-associated
lymphoid tissue in the gut in mice and humans [23, 110–
112]. Although most mature circulating NK cells do not
express IL-7Rα, experimental evidences have been provided
that thymic murine NK1.1+ cells express IL-7Rα and that
IL-7 is required for the homeostasis of these thymic NK
cells [108]. Indeed, diﬀerently from classical NK cells, the
development of thymic-derived NK cells is dependent upon
IL-7 and GATA-3 transcription factor [108]. This peculiar
subset is characterized by low cytotoxic activity but high
cytokine secretion potential.
As u b s e to fC D 5 6 +NKp44+ cells has been identiﬁed in
human tonsils, and mucosae-associated lymphoid tissues of
the gut. Since these cells secrete IL-22 in response to IL-
23, they were termed “NK-22” cells [112]. Similar to Th17
cells, NK-22 cells express the transcription factors retinoic-
acid-related orphan receptor RORγt and aryl hydrocarbon
receptor but do not produce IL-17. IL-7 supports the NK-
22 cell survival and maintains the ability to secrete IL-22 in
response to IL-23 stimulation.I na d d i t i o n ,t h ec o m b i n a t i o n
ofIL-7 with IL-1β orIL-2 also mediatesNK-22proliferation,
indicating a synergistic eﬀect of IL-7 with these cytokines
[22]. The use of IL-1β and/or IL-2 altered the cytokine
proﬁle of NK22 cells, suggesting their functional plasticity.
Indeed, IL-1β induced constitutive IL-22 secretion, while IL-
2reducedsecretion ofIL-22 and inducedproductionofIFN-
γ.
A murine equivalent of NK-22 cells has been identi-
ﬁed in gut-associated lymphoid tissues [20]o nt h eb a s i s
of their expression of the natural cytotoxicity receptor
(NCR) NKp46, a speciﬁc marker of NK cells from several
species [113]. This subset was phenotyically characterized as
NKp46+IL-7Rα+RORγt+ and depends for its development
on IL-7, RORγt, and intestinal microbial ﬂora [20, 110].
Diﬀerent from classical NK cells, the development of these
mucosal-associated NK cells does not require on IL-15 or
IL-2Rβ. Altogether, these data suggest that IL-22–producing
NKp46+IL-7Rα+RORγt+ cells and classical NK cells develop
through diﬀerent pathways under the control of diﬀerent
cytokines [20].
Since intestinal mouse CD3−NKp46+ and human NK-
22 cells have some features of immature NK cells, they may
possibly represent NK cell precursors that develop locally
into specialized NK cell subsets, under the inﬂuence of
a speciﬁc cytokine milieu and microbial product stimulation
[23, 111]. In addition, a population of IL-22-producing
immature NK cells showing a CD34−IL-7Rα+CD161+CD9−
surface phenotype, which do not produce IFN-γ and lack
of cytolytic activity, has been described in human secondary
lymphoid organs [114].
A recent report showed that rare human CD34+ hema-
topoietic progenitors develop into NK cells in vitro in the
presence of cytokines, such as IL-7, IL-15, SCF, and FLT3L.
Moreover, the addition of hydrocortisone and stromal cells
enhanced the frequency of progenitor cells that could
develop into killer cell Ig-like receptor (KIR)+NK cells [115].
These data suggest that NK cells can be derived from
precursor cells committed to the myeloid lineage. This latter
point is also supported by the existence of human CD14+
myeloid-like cells within cord blood behaving as a novel
progenitor for NK cells. Indeed, this CD14+ myeloid-like
subset can be redirected into NK diﬀerentiation in the
presence of IL-15 and then generates mature functional NK
cells [116].
CD34+ hematopoietic precursors in human decidua
were recently found to express IL-2Rβ,I L - 7 R α,a n dm R N A
for E4BP4 and ID2 transcription factors involved in NK
cell development [117]. These data suggested that decidual
CD34+ cells are precursors committed to the NK cell lineage.
In fact, these cells diﬀerentiate into functional IL-8- and
IL-22-producing CD56brightCD16−KIR+/− NK cells in the
presence of growth factors (including IL-15 and IL-7) or
upon coculture with decidual stromal cells.
7.IL-21 asaRegulatorofNK Cell Responses
IL-21 is produced by CD4+ T cells in response to antigen
presentation by DC during the adaptive immune response.
At this stage, murine NK cells have been already activated by
IL-12 and IL-15 produced by DC and then IL-21 can further
support their proliferation and induce their functional
maturation into potent eﬀector cells with large granular
lymphocyte morphology [118]. Thus, IL-21 upregulates the
expression of CD16, the Fc-γRIII required for in antibody-
dependent cellular cytotoxicity (ADCC), costimulates the
secretion of IFN-γ, and upregulates the expression of
granzyme and perforins. Similarly, IL-21 potentiates human
NK cell ADCC activity and their ability to secrete cytokines8 Journal of Biomedicine and Biotechnology
in response to antibody-coated tumor target cells [119]. IL-
21 is also capable to boost NK-mediated ADCC in NK cells
with defective cytotoxic properties, such as those of head-
and-neckcancerpatients[120].However,diﬀerentfromIL-2
andIL-15,IL-21alonedoesnotmediateNKcellproliferation
though at low concentrations, it costimulates the mitogenic
eﬀect of IL-2 or IL-15 [121, 122]. Although it is clear that
IL-21 is an important regulator of NK cell functions [30], IL-
21 may display positive and negative eﬀects on NK cells, in
relationship to their activation/maturation stage and species
of origin. In fact, remarkable diﬀerences in IL-21 activity
havebeen observedin mouse and human NKcells. Although
IL-21 costimulates several functional properties of IL-15-
activated murine NK cells, such as IFN-γ production and
cytotoxicity, it does not support their survival. Instead, IL-
21, at high concentrations, limits the proliferation of NK
cells mediated by IL-15 and promotes an apoptotic program.
Thus, ithasbeen proposedthatIL-21 mediatesthetransition
of an early innate towards an adaptive response in the
mouse, through the elimination of terminally diﬀerentiated
NK cells and the induction of cytotoxic T lymphocyte (CTL)
memory responses [123]. Diﬀerently, IL-21 alone stimulates
the cytolytic activity of freshly isolated, peripheral human
NK cells and the combination of low concentrations IL-21
plus IL-15 costimulates the expansion of CD56+CD16+ NK
cells, which develop strong eﬀector functions [121]. Possible
explanations for these discrepancies may relate not only to
speciesdiﬀerencesbutalsototheconcentrationsofIL-21and
IL-15 that were used in the diﬀerent experiments or on the
timing and activation state of NK cells.
NKG2D is an important activation receptor on mouse
and human NK cells and triggers cytotoxicity upon engage-
ment with ligands, such as antibodies or cell surface ligands.
These eﬀectsare mediated throughDNAX-activatingprotein
of 10 kDa (DAP10). Data in a mouse tumor model showed
that IL-21 is able to enhance tumor rejection through an
NKG2D-dependent mechanism [124] as NKG2D-blocking
inhibited the antitumor activity and cytotoxicity of IL-21
activated NK cells. On the opposite, treatment of human
NK and CD8+ T cells with IL-21 in combination with IL-2
reduces the cell surface expression of NKG2D and its ability
to trigger cytotoxicity,relative to cells treated with IL-2 alone
[125]. IL-21-induced downregulation of NKG2D is related
to inhibition of DAP10 gene transcription. However, IL-21
inducedtheexpressionoftheNKactivationreceptorsNKp30
and 2B4, suggesting that IL-21 modulates human NK cell
functions and their target speciﬁcity by altering the expres-
sion levels of diﬀerent activation/costimulatory receptors.
IL-21 also induced an accelerated development of
NK cells from human cord blood CD34+ haematopoietic
progenitor cells, in concert with IL-7, IL-15, and SCF.
Indeed IL-21 costimulates the expression of NKp46 and
NKp30triggering receptors, CD94/NKG2Ainhibitoryrecep-
t o r ,K I R s ,C D 2 ,a n dC D 1 6 ,t y p i c a lo fm a t u r eN Kc e l l sa n d
the acquisition of cytotoxic activity [126]. In addition, also
rare CD34−lineage− cells cultured with Flt3-L, SCF prolifer-
ated in response to IL-15 and IL-21 and acquired a
KIR−CD56+CD16−/+ lymphoid phenotype, consistent with
pseudomatureNK cells. These cells secreted IFN-γ,G M - C S F
andMIP-1α, anddisplayedcellsurface CD107auponcontact
with NK-sensitive targets [127]. Thus IL-21 may possibly
havearoleinthedevelopmentofNKcellsalthoughthestudy
ofIL-21K OmiceindicatedthatIL-21isnotstrictlynecessary
for the diﬀerentiation of NK cells from progenitors [56].
8.P erspecti v esforCanc erI mm unotherapy
IL-2representsamilestoneinthehistoryoftheimmunother-
apy of cancer and is still clinically used for the treatment of
advanced melanoma and renal carcinoma. The induction of
some long-lasting remissions in metastatic patients treated
with recombinant (r)IL-2 alone or in combination with LAK
cellsprovidedanimportant proofofprinciplethatactivation
of the immune system may result in tumor rejection even in
patientswithbulkydisease [128].However,theseeﬀectswere
observed in a minor subset of patients and the treatment
showed a remarkable toxicity, predominantly related to
“vascular leak syndrome” [129]a n da d v e r s ee ﬀects on the
heart [128]. The availability of novel recombinant cytokines
may oﬀer new possibilities for cancer immunotherapy [130,
131].
The functional properties of IL-15 have suggested the
use for this cytokine in tumor immunotherapy [12]. It is
hoped that IL-15 may display lower toxic eﬀects than IL-2
and provide similar immune-enhancing eﬀects on tumor-
reactive T and NK cells. In early experiments, tumor cells
transduced with a modiﬁed IL-15 cDNA, allowing enhanced
IL-15 secretion, showed reduced tumorigenic potential in
immunodeﬁcient [132]o ri ns y n g e n e i cm i c e[ 133], through
the recruitment of NK cells and/or CTLs. In addition, IL-
15-transduced tumor cells, administered as vaccine, reduced
the incidence of experimental metastases in syngeneic mice.
Administration of rIL-15 has also been shown to display
antitumor activity in murine tumor models with a lower
toxicitythanrIL-2 [134].Finally,plasmid genetransfer of IL-
15 trough an hydrodynamic method increases the number
and function of NK and IFN-producing killer DC cells in
mice [135].
In a preclinical study, human rIL-15, administered intra-
venously daily for 12 days to rhesus macaques, showed both
short- and long-lasting eﬀectson lymphoid cell homeostasis.
A transient lymphopenia preceded a clearcut increase in
NK and memory CD8+ T cells in the peripheral blood.
An inverted CD4/CD8 T-cell ratio was observed as result
of CD8+ T cell expansion. By day 48, homeostasis appears
restored throughout the body, with the exception of the
maintenance of an inverted CD4/CD8 ratio in lymph nodes
[136]. A phase I study of intravenous rIL-15 in adults with
refractory metastatic melanoma and renal cancer has been
recently started and is currently recruiting participants. The
objectives of this study are the evaluation of the safety and
eﬃcacy of rIL-15 and to examine how the body processes the
infused cytokine [NCT01021059].
Since the scaling up of IL-15 production for clinical
purposes has been technically diﬃcult, the possible usage of
hyper IL-15 in clinicalsettings of cancerimmunotherapy can
be envisaged. The potential advantages are that hyper-IL-15Journal of Biomedicine and Biotechnology 9
would act in lower doses than IL-15, as it is a more potent
activator of the immune system than IL-15 on a molar basis.
Interestingly, the potential development of hyper-IL-15 in
NK-based immunotherapy is also illustrated by data from
Kroemer et al. [137] in a skin transplant in Rag
−/− mice.
Resting NK cells did not reject skin allografts, while hyper-
IL-15-stimulated NK cells mediated acute skin allograft
rejection in the absence of T and B cells.
ThetransferofNKcellsisanemergingstrategyforcancer
immunotherapy, particularly in haematologic neoplasia.
A pivotal role in the antileukemic eﬀects of allogeneic NK
cell transfer is played by KIRs, which are inhibitory receptors
for HLA class I molecules [138]. The engagement of a KIR
expressed on the NK cell surface by the appropriate HLA
class I allele on a target cell produces an inhibitory signal
to the NK cell activation resulting in target cell protection.
In T cell-depleted haploidentical hematopoietic stem cell
transplantation (haplo-HSCT) donor NK cells may express
KIR(s) that do not recognize the HLA-class I alleles present
on recipient’s cells. In this “KIR-mismatch” setting, these
“alloreactive” NK cells eﬃciently lyse leukemiccells and gen-
erate a strong graft versus leukemia eﬀect, which contributes
in eradicating residual disease. In addition, alloreactive NK
cells eliminate residual host dendritic cells, thus preventing
graft-versus-host disease [138].
Because NK cells are a fraction of peripheral blood
mononuclear cells the development of methods to produce
large numbers of functional NK cells could be useful to opti-
mize NK-based therapies. Coculture of NK cells with K562
leukemia cells, genetically modiﬁed to express membrane-
bound IL-15 and 41BBL, allowed a 20-fold expansion of
CD56+CD3− NK cells from peripheral blood but induced
no proliferation of T cells. The expanded NK cells were
potent eﬀectors against acute myeloid leukemia cells (AML)
in vitro and eradicated AML in xenograft models in immun-
odeﬁcient mice. This method provide a new platform for
expanding activated NKcells for cell therapy of cancer[139].
In view of its immune-enhancing functions, also IL-
21 has been considered as a good candidate for can-
cer immunotherapy. In addition, IL-21, diﬀerently from
IL-2 is unable to mediate the proliferation of activated
CD4+CD25+Foxp3+ Treg cells in vitro [140]a l t h o u g hT r e g
cells express IL-21R gene. Nonetheless also IL-21 has shown
immune regulatory functions related to the induction of
IL-10 production, which inhibits the immune response by
acting at several levels [141]. Although this may represent
a potential drawback, it is almost likely that each immune
enhancing cytokine possess its own negative regulatory
mechanisms, to prevent exaggerated responses and autoim-
mune reactivity.
Several studies in murine tumor models has shown that
IL-21 is endowed with antitumor properties [142, 143],
which can be mediated by NK, T, or B cell-dependent re-
sponses, in relationship to the experimental model consid-
ered.
Diﬀerent types of tumor cells, genetically modiﬁed
to produce IL-21, form small tumors when injected into
syngeneic mice and are then eventually rejected by an IL-21-
driven immune reaction, which is followed by immunity to
tumor antigens [144]. In addition, human pancreatic cancer
cells transduced with murine IL-21 gene are rejected when
xenografted in immune-deﬁcient mice through activation
of NK cells [145]. In a syngeneic model of mammary
adenocarcinoma, tumor-released IL-21 induced the local
recruitment of both CD8+ and NK cells and the produc-
tion of IFN-γ and of IFN-γ-dependent CXC chemokines,
which mediated local antiangiogenic eﬀects [144]. IL-21-
transduced tumor cells were also eﬀective when used as
a vaccine to treat metastatic tumors [140, 146]. However,
in the mammary adenocarcinoma model, the therapeutic
eﬀect was partial and could be synergistically enhanced
by targeting CD4+CD25+ Treg cells by an anti-CD25 mAb
[140]. Thus, Treg cells appeared to limit not only CTL-
but also NK-mediated responses by tumor-released IL-21.
The antitumor eﬀects of IL-21 therapy did not require Th
cells, suggesting that IL-21 may bypass the requirement of
Th cells for the induction of CTL and NK responses. In a
neuroblastoma syngeneic model the eﬃcacy of IL-21-based
immunotherapy wasevenenhanced by transient CD4+ Tc el l
depletion, which also resulted in the elimination of CD4+
Treg cells [147].
Anotherapproach has beenthedirect genetransfer ofIL-
21 in vivo through a plasmid-based hydrodynamic system,
which results in sustained IL-21 levels and NK-dependent
antitumor eﬀects in syngeneic tumor models [148]. The
coinjection of IL-15- and IL-21-encoding plasmids in mice
bearing lymphoma produced cooperative eﬀects of tumor
rejection [149]. Also, the injection of plasmids encoding for
anIL-21/IgFcchimericproteinmediatedantitumoreﬀectsin
melanoma-bearing syngeneicmice, throughtheinduction of
anNK-mediatedresponse [150].OtherstudiescombinedIL-
21 protein administration with antibody treatments. In view
of the ability of IL-21 to enhance ADCC activity by NK cells,
rIL-21 has been combined with an anti-Her2/neu antibody
to treat mice bearing Her2/neu+ tumors. This combination
showed a synergistic antitumor eﬀect through an IFN-γ-
dependent mechanism [119].
Altogether preclinical studies led to the design of clinical
trials in cancer patients. Several clinical studies of rIL-21
monotherapy or combining IL-21 with other drugs are now
ongoing in diﬀerent type of cancers. Phase I studies in
melanoma andrenal cancerhavebeenalready concludedand
showed that IL-21 has an acceptable toxicity proﬁle and does
not induce vascular-leak syndrome by repeated iv infusion
[151, 152] or subcutaneous administration [153]. IL-21
induced increased levels of soluble CD25 and upregulated
IFN-γ, perforin, and granzyme B expression in circulating
CD8+ T cells and NK cells, indicating cytotoxic lymphocyte
activation. By i.v., IL-21 induced a dose-dependent decrease
in circulating NKand T cells, followed bya return tobaseline
in resting periods. Objective responses and disease stabiliza-
tions were observed and were also conﬁrmed in an initial
phaseIIclinicalstudy[154],which also suggestedanincrease
in progression-free survival.
Besides immune-enhancing activities, IL-21 mediates
apoptosis of speciﬁc Bcell malignancies such as chronic lym-
phocyticleukemia[34, 35]and follicular [37]o rd i ﬀuse large
Bc e l ll y m p h o m a[ 36]. CD4+CD25+ regulatory T cells are10 Journal of Biomedicine and Biotechnology
expanded in solid and hematological malignancies including
CLL and the use of IL-21 instead of IL-2 may contribute to
limit this expansion [155]. For this reason and for the ability
of IL-21 to enhance ADCC activity by NK cells, a phase I
trial of rIL-21 combined with the anti-CD20 mAb rituximab
has beendesigned in chemotherapy refractory/relapsed non-
Hodgkin’s lymphoma. Acceptable toxicity, several objective
responses, and disease stabilizations were reported in a
preliminary analysis of data [156]. Overall data from early
clinical trials indicate that IL-21 warrants further testing,
particularly in multimodality therapy regimens for cancer.
IL-21 also plays a role in controlling chronic viral
infections and its serum levels were reduced in HIV-infected
persons, which display defective NK activity. Two recent
reports indicated that IL-21 enhanced viability, HIV-speciﬁc
ADCC, IFN-γ secretion, and cytotoxic functions of NK cells
from HIV-infected persons [157, 158]. In addition, the IL-
21-activated NK cells inhibit viral replication in cocultured
CD4+ T cells. These data suggest that that IL-21 could
represent a potential tool for immunotherapy or as adjuvant
for vaccines in HIV-infected patients.
The systemic administration of cytokines at high doses
frequently results in toxicities, and the amount of cytokine
eﬀectively delivered at the tumor site is generally low. Tumor
cells genetically modiﬁed to secrete cytokines may elicit
potent immune responses upon injection in syngeneic mice,
without systemic eﬀects, due to a high local concentration of
cytokine. Although cytokine gene transfer procedures have
shown some promising eﬀects in easily accessible tumors
(such as subcutaneous melanoma metastases) [159], it can-
not be easily applied in case of systemic metastases. Another
possibility to reduce systemic toxicity and reach high cy-
tokine concentrations at the tumor site is based on the
targeted delivery of cytokines, through the generation of
fusion proteins formed by a recombinant antibody linked to
acytokine.Theseantibody/cytokinechimeras, deﬁnedasim-
munocytokines, have shown promising results in animal
models [160]. An example of such immunocytokines is L19-
IL-2 [161], which was obtained by chimerization of IL-2
with a single-chain human antibody speciﬁc for an oncofetal
ﬁbronectin isoform of the tumor extracellular matrix. L19-
IL-2 was capable to accumulate at sites of neoangiogenesis
in tumors, to determine the recruitment of T and NK and
to induce tumor regression in both syngeneic and nude
mice. Therefore, L19-IL-2 has entered several clinical trials
in diﬀerent types of tumors and a phase I study was recently
concluded [NCT01058538] [162]. This study showed that
L19-IL-2 can be safely and repeatedly administered in
advanced solid tumours and preliminary evaluation suggests
clinical activity in patients with metastatic renal carcinoma.
In a murine neuroblastoma model, the therapeutic eﬀect
of an immunocytokine consisting of an anti-GD2 antibody
linked to IL-2 was dependent on NK cells [163]. In addition,
most human neuroblastomas express low levels of HLA class
I[164]andexpressligandsforNCRactivatingreceptors,thus
representing potential targets for NK-based therapies [165].
A phase II trial of the humanized anti-GD2 monoclonal
antibody linked to human IL-2 (hu14.18-IL2) was recently
performed on relapsed/refractory neuroblastoma patients.
To explore the role of NK cells in this treatment patients
were genotyped for KIR, HLA, and FcR alleles. The presence
of a KIR/KIR-ligand mismatch was signﬁcantly associated
with response/improvement to immunocytokine, and there
was a trend towards a higher response rate in patients with
the FcγR2A 131-H/H genotype than other genotypes. These
ﬁndings are strongly suggestive for a role of NK cells in
clinical responses to hu14.18-IL2 cytokine treatment in
relapsed/refractory neuroblastoma patients [166].
9.Conclusions
In conclusion, several evidences indicate that IL-2, IL-7,
IL-15, and IL-21 play important roles in NK cell biology
and that, in spite of some redundancy, each cytokine has
clearly distinct functions. In addition, they may diﬀerentially
act on subset of NK cells, whose phenotypic and func-
tional heterogeneity is now well established. Moreover,
these cytokines allow to manipulate and expand NK cells
in vitro to generate populations with increased eﬀector
functions or to directly boost NK cell activity in vivo. Thus,
these cytokines may represent potentially relevant tools for
NK-based immunotherapy strategies in diseases such as
leukemias, solid tumors, and AIDS. In this context, the
development of novel strategies of cytokine targeted delivery
or the use of synergistic combinations with antibodies or
of diﬀerent cytokines may oﬀer the possibility to maximize
their therapeutic potential.
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